Carfilzomib (PR-171)
by Jessica Langholtz
Updated: Dec 9, 2009
Updated: Dec 9, 2009
| Brand Name: | |
| Generic Name: | carfilzomib |
| Code Name: | PR-171 |
| Company: | Onyx Pharmaceuticals |
| FDA Clinical Phase: | 1, 2, & 3 |
Description:
Carfilzomib (news articles), which is a second-generation proteasome inhibitor, selectively targets the enzymes that break down important proteins in cancerous cells. Multiple early-stage studies have shown that carfilzomib has an encouraging safety profile, with low levels of neuropathy (a common side effect for many myeloma treatments). A Phase 2 trial with relapsed and refractory myeloma patients has recently closed enrollment, and results are expected in late 2010.
Clinical Trials:
For a list of clinical trials studying carfilzomib for the treatment of multiple myeloma, see ClinicalTrials.gov.
Official Web site for Carfilzomib: http://www.onyx-pharm.com/view.cfm/632/Carfilzomib
Related Articles:
- Onyx Pharmaceuticals To Acquire Proteolix, Developer Of Carfilzomib
- Carfilzomib Is Highly Active In Relapsed Myeloma Patients
- ASH 2008 – Carfilzomib, A Novel Drug Related To Velcade, Reduces Peripheral Neuropathy
- Beacon BreakingNews – Onyx Submits Carfilzomib For FDA Approval
- Carfilzomib Application For FDA Approval Is Delayed
Leave a comment